Salicylic acid

Description

The drug is identified by SPL code 34089-3. It is presented as a white to off-white, round, biconvex tablet, which is debossed with "XYZ" on one side and "123" on the opposite side. Each tablet contains 500 mg of the active ingredient. The formulation includes inactive ingredients such as lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, and magnesium stearate.

Uses and Indications

This drug is indicated for the topical treatment of warts. Patients should begin by washing the affected area and may soak the wart in warm water for 5 minutes to facilitate treatment. After drying the area thoroughly, the patient should use the provided applicator (cotton swab) to apply a layer of ointment that sufficiently covers each wart. It is essential to allow the ointment to fully absorb, and a bandage may be applied as needed.

The application procedure should be repeated once or twice daily as necessary until the wart is removed, with a maximum treatment duration of up to 12 weeks.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The recommended procedure should be performed once or twice daily as needed, continuing until the wart is removed. This treatment may be administered for a maximum duration of 12 weeks. Healthcare professionals should monitor the patient's progress and adjust the frequency of application based on the individual response to therapy.

Contraindications

Use of this product is contraindicated in the following situations:

Application on damaged skin, including areas with cuts, abrasions, eczema, or sunburn, is not recommended due to the potential for irritation and adverse reactions.

Patients with a known allergy to any of the ingredients in this product should avoid its use to prevent allergic reactions.

The product is also contraindicated in pregnant or breastfeeding individuals, as safety during these conditions has not been established.

Warnings and Precautions

The liquid formulation is prone to volatilization and crystallization; therefore, it is imperative to securely tighten the cap after each use to maintain its integrity. Prolonged exposure to air should be avoided to ensure optimal performance of the product.

This product is intended for external use only. It must not come into contact with the eyes or be ingested. Children should utilize this product only under the supervision of an adult to prevent accidental misuse.

Caution is advised when applying the product to damaged skin, including areas with cuts, abrasions, eczema, or sunburn. Additionally, individuals with known allergies to any of the ingredients in this formulation should refrain from use. Special consideration should be given to pregnant or breastfeeding individuals, as the safety of the product in these populations has not been established.

No specific laboratory tests are recommended for monitoring the use of this product.

Side Effects

Patients should be aware that the product is for external use only and must not come into contact with the eyes or be ingested. It is advised that children use the product under the supervision of adults to ensure safety and proper application.

No specific adverse reactions have been reported in clinical trials or postmarketing experiences; however, the warnings emphasize the importance of adhering to the recommended usage guidelines to prevent potential harm.

Drug Interactions

There are no reported drug interactions associated with the use of this medication. Additionally, no interactions with laboratory tests have been identified. Therefore, no dosage adjustments or monitoring recommendations are necessary based on drug interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Tag Wart Remover. Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should use this medication under the supervision of adults to ensure proper administration and monitoring. It is essential to keep the medication out of reach of children to prevent accidental ingestion or misuse.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any adverse effects or changes in therapeutic response, given the lack of targeted data for this population.

Pregnancy

Pregnant patients and those who are breastfeeding should be advised to consult their healthcare provider before using this medication. The potential risks and benefits must be carefully weighed, as the effects on fetal outcomes and breastfeeding infants are not fully established. It is essential for women of childbearing potential to discuss their pregnancy status and any plans for pregnancy with their healthcare provider to ensure appropriate management and monitoring during treatment.

Lactation

Lactating mothers should be aware of the potential implications of using this medication while breastfeeding. There is limited information available regarding the excretion of this drug in human breast milk and its effects on breastfed infants. Therefore, healthcare professionals are advised to weigh the potential benefits against the risks when considering the use of this medication in lactating mothers. It is recommended that lactating mothers consult their healthcare provider for personalized guidance.

Renal Impairment

There is no specific information regarding dosage adjustments, special monitoring, or safety considerations for patients with renal impairment. Healthcare professionals should exercise caution when prescribing to patients with reduced kidney function, as the absence of detailed guidance necessitates careful clinical judgment. Regular monitoring of renal function may be advisable in this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there is no information available regarding dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise from an overdose. Symptoms can vary widely depending on the substance involved and the individual patient's response.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should implement supportive care measures, which may include maintaining airway patency, providing supplemental oxygen, and monitoring vital signs.

Additionally, it is recommended to consult local poison control centers or relevant toxicology resources for guidance on specific management protocols and antidotes, if applicable.

Documentation of the incident, including the substance involved, estimated dose, and time of exposure, is crucial for effective management and follow-up care.

Nonclinical Toxicology

If you are pregnant or breastfeeding, there may be teratogenic effects associated with the use of this product. No non-teratogenic effects have been identified in the available data. Additionally, there is no information provided regarding animal pharmacology and toxicology.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep the product out of reach of children to prevent accidental ingestion or misuse. It is important to inform patients that the product should not be applied to damaged skin, including areas with cuts, abrasions, eczema, or sunburn, as this may lead to irritation or adverse effects.

Patients should be cautioned to disclose any known allergies to the ingredients in the product prior to use. Additionally, healthcare providers should discuss the implications of using the product during pregnancy or while breastfeeding, ensuring that patients understand the potential risks involved.

Before application, patients should wash the affected area thoroughly and may benefit from soaking the wart in warm water for approximately five minutes to enhance the effectiveness of the treatment. After soaking, it is essential for patients to dry the area completely.

When applying the ointment, patients should use the provided applicator, such as a cotton swab, to apply a layer of ointment that sufficiently covers each wart. They should be instructed to allow the ointment to be fully absorbed and to cover the area with a bandage if necessary.

Patients should be informed that this procedure may be repeated once or twice daily as needed, continuing until the wart is removed, but not exceeding a duration of 12 weeks.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available upon request. It is essential to store the product at a temperature range of 68°F to 77°F (20°C to 25°C). Care should be taken to protect the product from excessive heat, specifically temperatures exceeding 104°F (40°C). Proper storage conditions are crucial to maintain the integrity and efficacy of the product.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Tag Wart Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)